TY - JOUR AU - Waldmann, T. A. PY - 2018 DA - 2018// TI - Cytokines in cancer immunotherapy JO - Cold Spring Harb Perspect Biol VL - 3 ID - Waldmann2018 ER - TY - JOUR AU - K-p, H. AU - Zhu, X. AU - Liu, B. AU - Jeng, E. AU - Kong, L. AU - Yovandich, J. L. PY - 2011 DA - 2011// TI - IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization JO - Cytokine. VL - 56 UR - https://doi.org/10.1016/j.cyto.2011.09.028 DO - 10.1016/j.cyto.2011.09.028 ID - K-p2011 ER - TY - JOUR AU - Zhu, X. AU - Marcus, W. D. AU - Xu, W. AU - Hi, L. AU - Han, K. AU - Egan, J. O. PY - 2009 DA - 2009// TI - Novel human Interleukin-15 agonists JO - J Immunol VL - 183 UR - https://doi.org/10.4049/jimmunol.0901244 DO - 10.4049/jimmunol.0901244 ID - Zhu2009 ER - TY - JOUR AU - Xu, W. AU - Jones, M. AU - Liu, B. AU - Zhu, X. AU - Johnson, C. B. AU - Edwards, A. C. PY - 2013 DA - 2013// TI - Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/fc fusion complex in syngeneic murine models of multiple myeloma JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-12-2357 DO - 10.1158/0008-5472.CAN-12-2357 ID - Xu2013 ER - TY - JOUR AU - Rhode, P. R. AU - Egan, J. O. AU - Xu, W. AU - Hong, H. AU - Webb, G. M. AU - Chen, X. PY - 2016 DA - 2016// TI - Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models JO - Cancer Immunol Res VL - 4 UR - https://doi.org/10.1158/2326-6066.CIR-15-0093-T DO - 10.1158/2326-6066.CIR-15-0093-T ID - Rhode2016 ER - TY - JOUR AU - Conlon, K. C. AU - Lugli, E. AU - Welles, H. C. AU - Rosenberg, S. A. AU - Fojo, A. T. AU - Morris, J. C. PY - 2015 DA - 2015// TI - Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human Interleukin-15 in patients with cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.57.3329 DO - 10.1200/JCO.2014.57.3329 ID - Conlon2015 ER - TY - JOUR AU - Romee, R. AU - Cooley, S. AU - Berrien-Elliott, M. M. AU - Westervelt, P. AU - Verneris, M. R. AU - Wagner, J. E. PY - 2018 DA - 2018// TI - First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation JO - Blood. VL - 131 UR - https://doi.org/10.1182/blood-2017-12-823757 DO - 10.1182/blood-2017-12-823757 ID - Romee2018 ER - TY - JOUR AU - Margolin, K. AU - Morishima, C. AU - Velcheti, V. AU - Miller, J. S. AU - Lee, S. M. AU - Silk, A. W. PY - 2018 DA - 2018// TI - Phase I trial of ALT-803, a novel recombinant Interleukin-15 complex, in patients with advanced solid tumors JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-18-0945 DO - 10.1158/1078-0432.CCR-18-0945 ID - Margolin2018 ER - TY - JOUR AU - Kim, P. S. AU - Kwilas, A. R. AU - Xu, W. AU - Alter, S. AU - Jeng, E. K. AU - Wong, H. C. PY - 2016 DA - 2016// TI - IL-15 superagonist/IL-15RαSushi-fc fusion complex (IL-15SA/IL-15RαSu-fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.7470 DO - 10.18632/oncotarget.7470 ID - Kim2016 ER - TY - JOUR AU - Mathios, D. AU - Park, C. -. K. AU - Marcus, W. D. AU - Alter, S. AU - Rhode, P. R. AU - Jeng, E. K. PY - 2016 DA - 2016// TI - Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model JO - Int J Cancer VL - 138 UR - https://doi.org/10.1002/ijc.29686 DO - 10.1002/ijc.29686 ID - Mathios2016 ER - TY - JOUR AU - Liu, B. AU - Jones, M. AU - Kong, L. AU - Noel, T. AU - Jeng, E. K. AU - Shi, S. PY - 2018 DA - 2018// TI - Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models JO - Cytokine. VL - 107 UR - https://doi.org/10.1016/j.cyto.2017.12.003 DO - 10.1016/j.cyto.2017.12.003 ID - Liu2018 ER - TY - JOUR AU - Postow, M. A. AU - Callahan, M. K. AU - Wolchok, J. D. PY - 2015 DA - 2015// TI - Immune checkpoint blockade in cancer therapy JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.4358 DO - 10.1200/JCO.2014.59.4358 ID - Postow2015 ER - TY - JOUR AU - Zou, W. AU - Wolchok, J. D. AU - Chen, L. PY - 2016 DA - 2016// TI - PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations JO - Sci Transl Med VL - 8 UR - https://doi.org/10.1126/scitranslmed.aad7118 DO - 10.1126/scitranslmed.aad7118 ID - Zou2016 ER - TY - JOUR AU - Hamanishi, J. AU - Mandai, M. AU - Iwasaki, M. AU - Okazaki, T. AU - Tanaka, Y. AU - Yamaguchi, K. PY - 2007 DA - 2007// TI - Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer JO - Proc Natl Acad Sci U S A VL - 104 UR - https://doi.org/10.1073/pnas.0611533104 DO - 10.1073/pnas.0611533104 ID - Hamanishi2007 ER - TY - JOUR AU - Qing, Y. AU - Li, Q. AU - Ren, T. AU - Xia, W. AU - Peng, Y. AU - Gl, L. PY - 2015 DA - 2015// TI - Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer JO - Drug Des Devel Ther VL - 9 UR - https://doi.org/10.2147/DDDT.S75152 DO - 10.2147/DDDT.S75152 ID - Qing2015 ER - TY - JOUR AU - Robert, C. AU - Schachter, J. AU - Long, G. V. AU - Arance, A. AU - Grob, J. J. AU - Mortier, L. PY - 2015 DA - 2015// TI - Pembrolizumab versus ipilimumab in advanced melanoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1503093 DO - 10.1056/NEJMoa1503093 ID - Robert2015 ER - TY - JOUR AU - Topalian, S. L. AU - Sznol, M. AU - McDermott, D. F. AU - Kluger, H. M. AU - Carvajal, R. D. AU - Sharfman, W. H. PY - 2014 DA - 2014// TI - Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.53.0105 DO - 10.1200/JCO.2013.53.0105 ID - Topalian2014 ER - TY - JOUR AU - Carbone, D. P. AU - Reck, M. AU - Paz-Ares, L. AU - Creelan, B. AU - Horn, L. AU - Steins, M. PY - 2017 DA - 2017// TI - First-line nivolumab in stage IV or recurrent non-small-cell lung cancer JO - New Eng J Med. VL - 376 UR - https://doi.org/10.1056/NEJMoa1613493 DO - 10.1056/NEJMoa1613493 ID - Carbone2017 ER - TY - JOUR AU - Borghaei, H. AU - Paz-Ares, L. AU - Horn, L. AU - Spigel, D. R. AU - Steins, M. AU - Ready, N. E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer JO - New Eng J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1507643 DO - 10.1056/NEJMoa1507643 ID - Borghaei2015 ER - TY - JOUR AU - Bellmunt, J. AU - Wit, R. AU - Vaughn, D. J. AU - Fradet, Y. AU - Lee, J. -. L. AU - Fong, L. PY - 2017 DA - 2017// TI - Pembrolizumab as second-line therapy for advanced urothelial carcinoma JO - New Eng J Med. VL - 376 UR - https://doi.org/10.1056/NEJMoa1613683 DO - 10.1056/NEJMoa1613683 ID - Bellmunt2017 ER - TY - JOUR AU - Apolo, A. B. AU - Infante, J. R. AU - Balmanoukian, A. AU - Patel, M. R. AU - Wang, D. AU - Kelly, K. PY - 2017 DA - 2017// TI - Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.71.6795 DO - 10.1200/JCO.2016.71.6795 ID - Apolo2017 ER - TY - JOUR AU - Kinter, A. L. AU - Godbout, E. J. AU - McNally, J. P. AU - Sereti, I. AU - Roby, G. A. AU - O'Shea, M. A. PY - 2008 DA - 2008// TI - The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands JO - J Immunol VL - 181 UR - https://doi.org/10.4049/jimmunol.181.10.6738 DO - 10.4049/jimmunol.181.10.6738 ID - Kinter2008 ER - TY - JOUR AU - Wrangle, J. M. AU - Velcheti, V. AU - Patel, M. R. AU - Garrett-Mayer, E. AU - Hill, E. G. AU - Ravenel, J. G. PY - 2018 DA - 2018// TI - ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30148-7 DO - 10.1016/S1470-2045(18)30148-7 ID - Wrangle2018 ER - TY - JOUR AU - Clarke, P. AU - Mann, J. AU - Simpson, J. F. AU - Rickard-Dickson, K. AU - Primus, F. J. PY - 1998 DA - 1998// TI - Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy JO - Cancer Res VL - 58 ID - Clarke1998 ER - TY - JOUR AU - Robbins, P. F. AU - Kantor, J. A. AU - Salgaller, M. AU - Hand, P. H. AU - Fernsten, P. D. AU - Schlom, J. PY - 1991 DA - 1991// TI - Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line JO - Cancer Res VL - 51 ID - Robbins1991 ER - TY - STD TI - Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2001; Chapter 20:Unit 20.2. https://doi.org/10.1002/0471142735.im2002s39. PMID: 18432775. ID - ref26 ER - TY - JOUR AU - Ardiani, A. AU - Gameiro, S. R. AU - Palena, C. AU - Hamilton, D. H. AU - Kwilas, A. AU - King, T. H. PY - 2014 DA - 2014// TI - Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-13-2045 DO - 10.1158/0008-5472.CAN-13-2045 ID - Ardiani2014 ER - TY - JOUR AU - Anderson, K. G. AU - Mayer-Barber, K. AU - Sung, H. AU - Beura, L. AU - James, B. R. AU - Taylor, J. J. PY - 2014 DA - 2014// TI - Intravascular staining for discrimination of vascular and tissue leukocytes JO - Nat Protoc VL - 9 UR - https://doi.org/10.1038/nprot.2014.005 DO - 10.1038/nprot.2014.005 ID - Anderson2014 ER - TY - JOUR AU - Pulaski, B. A. AU - Ostrand-Rosenberg, S. PY - 1998 DA - 1998// TI - Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines JO - Cancer Res VL - 58 ID - Pulaski1998 ER - TY - JOUR AU - Sagiv-Barfi, I. AU - Kohrt, H. E. AU - Czerwinski, D. K. AU - Ng, P. P. AU - Chang, B. Y. AU - Levy, R. PY - 2015 DA - 2015// TI - Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK JO - Proc Natl Acad Sci U S A VL - 112 UR - https://doi.org/10.1073/pnas.1500712112 DO - 10.1073/pnas.1500712112 ID - Sagiv-Barfi2015 ER - TY - JOUR AU - Ouzounova, M. AU - Lee, E. AU - Piranlioglu, R. AU - Andaloussi, A. AU - Kolhe, R. AU - Demirci, M. F. PY - 2017 DA - 2017// TI - Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade JO - Nat Commun VL - 8 UR - https://doi.org/10.1038/ncomms14979 DO - 10.1038/ncomms14979 ID - Ouzounova2017 ER - TY - JOUR AU - Liu, Z. AU - Kim, J. H. AU - Falo, J. AU - Louis, D. AU - You, Z. PY - 2009 DA - 2009// TI - Tumor regulatory T cells potently abrogate antitumor immunity JO - J Immunol VL - 182 UR - https://doi.org/10.4049/jimmunol.0802664 DO - 10.4049/jimmunol.0802664 ID - Liu2009 ER - TY - JOUR AU - Spranger, S. AU - Luke, J. J. AU - Bao, R. AU - Zha, Y. AU - Hernandez, K. M. AU - Li, Y. PY - 2016 DA - 2016// TI - Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma JO - Proc Natl Acad Sci U S A VL - 113 UR - https://doi.org/10.1073/pnas.1609376113 DO - 10.1073/pnas.1609376113 ID - Spranger2016 ER - TY - JOUR AU - Sharma, P. AU - Hu-Lieskovan, S. AU - Wargo, J. A. AU - Ribas, A. PY - 2017 DA - 2017// TI - Primary, adaptive and acquired resistance to cancer immunotherapy JO - Cell. VL - 168 UR - https://doi.org/10.1016/j.cell.2017.01.017 DO - 10.1016/j.cell.2017.01.017 ID - Sharma2017 ER - TY - JOUR AU - Mall, C. AU - Sckisel, G. D. AU - Proia, D. A. AU - Mirsoian, A. AU - Grossenbacher, S. K. AU - Pai, C. S. PY - 2016 DA - 2016// TI - Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer JO - Oncoimmunology. VL - 5 UR - https://doi.org/10.1080/2162402X.2015.1075114 DO - 10.1080/2162402X.2015.1075114 ID - Mall2016 ER - TY - JOUR AU - Hesker, P. R. AU - Krupnick, A. S. PY - 2013 DA - 2013// TI - The role of natural killer cells in pulmonary immunosurveillance JO - Front Biosci (Schol Ed) VL - 5 UR - https://doi.org/10.2741/S391 DO - 10.2741/S391 ID - Hesker2013 ER - TY - JOUR AU - Omar, S. Y. AU - Marshall, E. AU - Middleton, D. AU - Christmas, S. E. PY - 2011 DA - 2011// TI - Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer JO - Immunology. VL - 133 UR - https://doi.org/10.1111/j.1365-2567.2011.03415.x DO - 10.1111/j.1365-2567.2011.03415.x ID - Omar2011 ER - TY - JOUR AU - Yang, Q. AU - Goding, S. R. AU - Hokland, M. E. AU - Basse, P. H. PY - 2006 DA - 2006// TI - Antitumor activity of NK cells JO - Immunol Res VL - 36 UR - https://doi.org/10.1385/IR:36:1:13 DO - 10.1385/IR:36:1:13 ID - Yang2006 ER - TY - JOUR AU - Ballbach, M. AU - Dannert, A. AU - Singh, A. AU - Siegmund, D. M. AU - Handgretinger, R. AU - Piali, L. PY - 2017 DA - 2017// TI - Expression of checkpoint molecules on myeloid-derived suppressor cells JO - Immunol Lett VL - 192 UR - https://doi.org/10.1016/j.imlet.2017.10.001 DO - 10.1016/j.imlet.2017.10.001 ID - Ballbach2017 ER - TY - JOUR AU - Lu, C. AU - Redd, P. S. AU - Lee, J. R. AU - Savage, N. AU - Liu, K. PY - 2016 DA - 2016// TI - The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells JO - OncoImmunology. VL - 5 UR - https://doi.org/10.1080/2162402X.2016.1247135 DO - 10.1080/2162402X.2016.1247135 ID - Lu2016 ER - TY - JOUR AU - Youn, J. -. I. AU - Nagaraj, S. AU - Collazo, M. AU - Gabrilovich, D. I. PY - 2008 DA - 2008// TI - Subsets of myeloid-derived suppressor cells in tumor-bearing mice JO - J Immunol VL - 181 UR - https://doi.org/10.4049/jimmunol.181.8.5791 DO - 10.4049/jimmunol.181.8.5791 ID - Youn2008 ER - TY - JOUR AU - Diefenbach, A. AU - Jensen, E. R. AU - Jamieson, A. M. AU - Raulet, D. H. PY - 2001 DA - 2001// TI - Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity JO - Nature. VL - 413 UR - https://doi.org/10.1038/35093109 DO - 10.1038/35093109 ID - Diefenbach2001 ER - TY - JOUR AU - Malladi, S. AU - Macalinao, D. G. AU - Jin, X. AU - He, L. AU - Basnet, H. AU - Zou, Y. PY - 2016 DA - 2016// TI - Metastatic latency and immune evasion through autocrine inhibition of WNT JO - Cell. VL - 165 UR - https://doi.org/10.1016/j.cell.2016.02.025 DO - 10.1016/j.cell.2016.02.025 ID - Malladi2016 ER - TY - JOUR AU - Spiegel, A. AU - Brooks, M. W. AU - Houshyar, S. AU - Reinhardt, F. AU - Ardolino, M. AU - Fessler, E. PY - 2016 DA - 2016// TI - Neutrophils suppress intraluminal NK cell–mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells JO - Cancer Discov VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-15-1157 DO - 10.1158/2159-8290.CD-15-1157 ID - Spiegel2016 ER - TY - JOUR AU - Chockley, P. J. AU - Chen, J. AU - Chen, G. AU - Beer, D. G. AU - Standiford, T. J. AU - Keshamouni, V. G. PY - 2018 DA - 2018// TI - Epithelial-mesenchymal transition leads to NK cell–mediated metastasis-specific immunosurveillance in lung cancer JO - J Clin Invest VL - 128 UR - https://doi.org/10.1172/JCI97611 DO - 10.1172/JCI97611 ID - Chockley2018 ER - TY - JOUR AU - Platonova, S. AU - Cherfils-Vicini, J. AU - Damotte, D. AU - Crozet, L. AU - Vieillard, V. AU - Validire, P. PY - 2011 DA - 2011// TI - Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-10-4179 DO - 10.1158/0008-5472.CAN-10-4179 ID - Platonova2011 ER -